Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5)
Year: 2021
Type: conference-abstract
Source: Cancer Research
Institutions: The University of Texas MD Anderson Cancer Center, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Kaiser Permanente Vallejo Medical Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Universitair Ziekenhuis Leuven, The Barbara Ann Karmanos Cancer Institute, Hadassah Medical Center, UC Davis Comprehensive Cancer Center, University of California, Davis, Virginia Cancer Specialists, AdventHealth Orlando
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3182276024